Skip to content

Iron Sucrose Versus Ferrous Bis-glycinate for Treatment of Iron Deficiency Anemia

Intravenous Iron Sucrose Versus Oral Ferrous Bis-glycinate for Treatment of Postpartum Iron Deficiency Anemia: a Randomized Clinical Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03009578
Enrollment
100
Registered
2017-01-04
Start date
2017-02-01
Completion date
2018-06-05
Last updated
2018-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Brief summary

Iron deficiency may result from inadequate dietary intake, achlorhydria or excessive ingestion of proton pump inhibitors, parasitic infestations, chronic infections and repeated pregnancies. Iron supplementation of antenatal patients is a basic tenet of antenatal care programmes in numerous developing and underdeveloped nations. Postpartum anemia is defined as hemoglobin of less than 11.5 gm% during the postpartum period. The prevalence of postpartum anemia varies from 4 - 27%. Chronic iron deficiency due to inadequate intake/ lack of iron supplementation during pregnancy, repeated pregnancies and postpartum hemorrhage are important causes of postpartum anemia

Interventions

iron Intramuscular injections

oral iron tablets

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

Hemoglobin level 7-11.5 gm/dl. No chronic diseases. Breastfeeding. Delivered at gestational age \>38 weeks. Within 24-72 hours postpartum. Women who accept to participate in the study

Exclusion criteria

1. Severe anemia \< 7 gm/dl. 2. Women received iron therapy during pregnancy. 3. Intolerance to iron preparations 4. Anemia due to other causes 5. Peripartum blood transfusion.

Design outcomes

Primary

MeasureTime frame
the percentage of patients achieving Hb rise 3 gm or more6 weeks

Secondary

MeasureTime frame
Mean rise of Hb from baseline to 6 weeks.6 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026